| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/04/2009 | EP2020237A2 Ceramide and chemotherapeutic agents for inducing cell death |
| 02/04/2009 | EP2019830A2 Inhibitors of secretion of hepatitis b virus antigens for treatment of a chronic hepatitis virus |
| 02/04/2009 | EP2019680A1 Augmentation of titer for vaccination in animals |
| 02/04/2009 | EP1127944B1 Methods for screening compounds inhibiting inflammatory cytokine production |
| 02/04/2009 | EP0821589B1 Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs |
| 02/04/2009 | CN101360500A Use of morpholino compounds for the treatment of halitosis |
| 02/04/2009 | CN101360486A Nanoparticles for protein drug delivery |
| 02/04/2009 | CN100457753C N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases |
| 02/04/2009 | CN100457728C Tyrosine kinase inhibitors |
| 02/04/2009 | CN100457190C Promoters exhibiting endothelial cell specificity and methods of using same |
| 02/04/2009 | CN100457189C Fusions of cytokines and tumor targeting proteins |
| 02/04/2009 | CN100457188C Implantable particles for tissue bulking and the treatment of gastroesophageal reflux diosease |
| 02/04/2009 | CN100457185C Coordination complex of diaminocyclohexaneplatinum(II) with block copolymer containing poly(carboxylic acid) segment and antitumor agent comprising the same |
| 02/04/2009 | CN100457184C Multi-stage oral drug controlled-release system |
| 02/04/2009 | CN100457183C Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination |
| 02/04/2009 | CN100457182C Behavior chemotherapy |
| 02/04/2009 | CN100457097C Composition for lowering blood glucose |
| 02/04/2009 | CN100457086C Aseptic medicine composition |
| 02/03/2009 | US7485710 Nucleic acids coding for adhesion factor of group B streptococcus, adhesion factors of group B streptococcus and further uses thereof |
| 02/03/2009 | US7485697 Nucleotide sequences coding receptor for advanced glycation endproducts (RAGE) for identifying modulators for treatment and prevention of cell proliferative and cardiovascular disorders |
| 02/03/2009 | US7485659 Anticancer compositions, and methods of making and using the same |
| 02/03/2009 | US7485653 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease |
| 02/03/2009 | US7485634 Methods for modulating the activity of receptors are provided. In particular compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of |
| 02/03/2009 | US7485628 Inhibition of STAT-1 |
| 02/03/2009 | US7485626 Biosynthesis of Dna ; cell proliferation; overlapping enzyme activation ; mixture of proteolytic enzyme and dipeptidyl peptidase inhibitors; autoimmune disease; antiinflammatory agents graft versus host diease |
| 02/03/2009 | US7485624 administering a neurotoxin, specifically a botulinum toxin, to treat disorders such as cardiac arrhythmias |
| 02/03/2009 | US7485456 Drug screening for a molecule capable of binding to NIK (nuclear factor kappa B inducing kinase); DNA sequence encoding a protein capable of binding to a tumor necrosis factor receptor-associated factor (TRAF) molecule, TRAF-binding proteins, isoforms, analogs, fragments and derivatives; gene expression |
| 02/03/2009 | US7485449 Nucleic acids encoding sodium channel scn3a alpha subunits |
| 02/03/2009 | US7485429 Genetically engineered polypeptide comprising extracellular domain of integrin subunit alpha 11; marker or target of all types of cells; drugs, vaccines |
| 02/03/2009 | US7485422 Using aberrant expression of caudal type homeobox transcription factor 2 (CDX2) as diagnostic indicator of stomach or esophageal cell proliferative disorers |
| 02/03/2009 | US7485326 Oral microemulsion composition comprising biphenyldimethyldicarboxylate and silybin |
| 02/03/2009 | US7485314 Induction of antigen specific immunologic tolerance |
| 02/03/2009 | US7485304 Non-toxic mucosal adjuvant |
| 02/03/2009 | US7485301 Complexing, therapy, prophylaxis, medical diagnosis; antibodies, antigen binding to chemokine |
| 02/03/2009 | US7485285 Delivery of antidepressants through an inhalation route |
| 02/03/2009 | CA2395881C Inhalation particles |
| 02/03/2009 | CA2392804C Combined agents for treatment of glaucoma |
| 02/03/2009 | CA2390463C 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block |
| 02/03/2009 | CA2361377C Novel mucosal delivery system |
| 02/03/2009 | CA2314607C Use of ppar-.gamma. activators in dermatology |
| 02/03/2009 | CA2282654C Use of cholinesterase inhibitors to treat attention deficit hyperactivity disorder |
| 01/30/2009 | CA2595671A1 Method and system for producing medicinal alcohol as a prophylatic or remedy for cancer, hiv, aids and autoimmune diseases |
| 01/29/2009 | WO2009014642A1 Combination of a de novo purine biosynthesis inhibitor and a cyclin dependent kinase inhibitor for the treatment of cancer |
| 01/29/2009 | WO2009014263A1 Agent for treatment of ophthalmia containing interleukin-6 receptor inhibitor as active ingredient |
| 01/29/2009 | WO2009013569A1 Pharmaceutical composition and pharmaceutical kit for the treatment of hepatocellular carcinoma |
| 01/29/2009 | WO2009013480A2 Antibacterial combination therapy |
| 01/29/2009 | WO2009013286A1 Organic compounds |
| 01/29/2009 | WO2009012907A1 Synergistic fungicidal active genistein combinations |
| 01/29/2009 | WO2009012590A1 Therapeutic formulations for the treatment of cold and flu-like symptoms |
| 01/29/2009 | WO2008142094A4 Triazol compounds for treating biofilm formation |
| 01/29/2009 | WO2008101469A3 Pharmaceutical preparation for treating metastases |
| 01/29/2009 | WO2008085074A8 1, 3-dihydroimidazoles for treating cardiovascular disorders |
| 01/29/2009 | WO2008075201A3 Epigallocatechin-3-gallate compositions for cancer therapy and chemoprotection |
| 01/29/2009 | WO2008046882A3 Composition comprising an nk-1 receptor antagonist and an ssri for the treatment of tinnitus and hearing loss |
| 01/29/2009 | WO2007139821A3 Methods of using lrr superfamily genes and proteins |
| 01/29/2009 | US20090030525 Method for restoring a damaged or degenerated intervertebral disc |
| 01/29/2009 | US20090030056 Novel sodium channel blockers |
| 01/29/2009 | US20090030051 Inhibitors of IMPDH enzyme |
| 01/29/2009 | US20090030032 Bicyclic Compound, Production and Use Thereof |
| 01/29/2009 | US20090029967 Adenosine a2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders |
| 01/29/2009 | US20090029959 Antiglucocorticoid Therapy for the Prevention of Neurological Damage in Premature Infants |
| 01/29/2009 | US20090029922 Use of S1P receptor agonists in heart diseases |
| 01/29/2009 | US20090029415 Peripheral nervous system specific sodium channels, DNA encoding therefor, crystallization, X-ray diffraction, computer molecular modeling, rational drug design, drug screening, and methods of making and using thereof |
| 01/29/2009 | US20090029400 Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| 01/29/2009 | US20090029361 Growth differentiation factor-7 |
| 01/29/2009 | US20090028904 Novel cochleate formulations |
| 01/29/2009 | US20090028882 Methods of inhibiting binding of beta-sheet fibril to rage and consequences thereof |
| 01/29/2009 | US20090028867 Antagonists Specific For Denatured Collagen And Methods Of Using Same |
| 01/29/2009 | US20090028861 Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes |
| 01/29/2009 | US20090028850 Prolongation of survival of an allograft by inhibiting complement activity |
| 01/29/2009 | CA2731801A1 Therapeutic formulations for the treatment of cold and flu-like symptoms |
| 01/29/2009 | CA2694267A1 Pharmaceutical composition and pharmaceutical kit for the treatment of hepatocellular carcinoma |
| 01/29/2009 | CA2693544A1 Antibacterial combination therapy |
| 01/28/2009 | EP2018874A2 Pharmaceutical compositions for the prevention and treatment of central nervous system disorders comprising a nicotinic compound and an acetylcholinesterase inhibitor |
| 01/28/2009 | EP2018873A1 Prophylactic/therapeutic agent for cancer |
| 01/28/2009 | EP2018872A1 Pharmaceutical product |
| 01/28/2009 | EP2018865A2 Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an lhrh analogue and/or a bisphosphonate |
| 01/28/2009 | EP2018858A1 Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic trioxide |
| 01/28/2009 | EP2018856A2 Multi-part medicinal product for wound cleansing and healing |
| 01/28/2009 | EP2018852A1 Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
| 01/28/2009 | EP2018185A1 Use of mas-g-protein-coupled receptor agonists in the treatment of the metabolic syndrome, its components and its complications |
| 01/28/2009 | EP2018170A2 Medication against breast cancer and related diseases |
| 01/28/2009 | EP2018164A2 Use of combination preparations comprising antifungal agents |
| 01/28/2009 | EP1553922B1 Salmeterol superfine formulation |
| 01/28/2009 | EP1435927B1 Use of totarol for the treatment of pruritus |
| 01/28/2009 | EP1372716B1 Blood cell production via activation of cd163 |
| 01/28/2009 | EP1073416B1 Use of inhaled no as anti-inflammatory agent |
| 01/28/2009 | CN101355969A Antiproliferative combination comprising CYC-682 and a cytotoxic agent |
| 01/28/2009 | CN101355968A Compositions and methods for treating thrombocytopenia |
| 01/28/2009 | CN101355948A Combination of Roscovitine and a HDCA inhibitor to treat prolifeative diseases |
| 01/28/2009 | CN101354397A Strategy for retroviral immunotherapy |
| 01/28/2009 | CN101352454A External-use gel foamable composition for gynecology inflammation and obesity |
| 01/28/2009 | CN101352426A Osmotic pump controlled release preparation composition and preparation thereof |
| 01/28/2009 | CN101352425A Compound osmotic pump controlled release preparation and preparation method thereof |
| 01/28/2009 | CN101352421A Method for preparing basically non-crystalline type telmisartan |
| 01/28/2009 | CN101352412A Intestinal-lysis non-steroidal antipyretic-antalgic anti-inflammatory agent and preparation thereof |
| 01/28/2009 | CN101352234A Composition comprising alkaline sphingomyelinase for use as a dietetic preparation, food supplement or pharmaceutical product |
| 01/27/2009 | US7482466 Hydroxamates as therapeutic agents |
| 01/27/2009 | US7482458 Quinoline derivatives |
| 01/27/2009 | US7482433 Peptides of sequence of amino acids where one or more of the peptidyl [ C(O)NR ] linkages (bonds) have been replaced by a non-peptidyl linkage; IL-5 antagonists treating asthma |